3078 related articles for article (PubMed ID: 21721431)
1. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic impact of CSF biomarkers in a local hospital memory clinic.
Kester MI; Boelaarts L; Bouwman FH; Vogels RL; Groot ER; van Elk EJ; Blankenstein MA; van der Flier WM; Scheltens P
Dement Geriatr Cogn Disord; 2010; 29(6):491-7. PubMed ID: 20523047
[TBL] [Abstract][Full Text] [Related]
3. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
Chiasserini D; Parnetti L; Andreasson U; Zetterberg H; Giannandrea D; Calabresi P; Blennow K
J Alzheimers Dis; 2010; 22(4):1281-8. PubMed ID: 20930282
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.
Smach MA; Charfeddine B; Ben Othman L; Lammouchi T; Dridi H; Nafati S; Ltaief A; Bennamou S; Limem K
Eur Neurol; 2009; 62(6):349-55. PubMed ID: 19786779
[TBL] [Abstract][Full Text] [Related]
7. Added diagnostic value of CSF biomarkers in differential dementia diagnosis.
Le Bastard N; Martin JJ; Vanmechelen E; Vanderstichele H; De Deyn PP; Engelborghs S
Neurobiol Aging; 2010 Nov; 31(11):1867-76. PubMed ID: 19150153
[TBL] [Abstract][Full Text] [Related]
8. Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects.
Verwey NA; Kester MI; van der Flier WM; Veerhuis R; Berkhof H; Twaalfhoven H; Blankenstein MA; Scheltens And P; Pijnenburg YA
J Alzheimers Dis; 2010; 20(2):445-52. PubMed ID: 20164558
[TBL] [Abstract][Full Text] [Related]
9. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study.
Jongbloed W; Kester MI; van der Flier WM; Veerhuis R; Scheltens P; Blankenstein MA; Teunissen CE
Alzheimers Dement; 2013 May; 9(3):276-83. PubMed ID: 23110867
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.
Formichi P; Battisti C; Radi E; Federico A
J Cell Physiol; 2006 Jul; 208(1):39-46. PubMed ID: 16447254
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration.
Kapaki E; Paraskevas GP; Papageorgiou SG; Bonakis A; Kalfakis N; Zalonis I; Vassilopoulos D
Alzheimer Dis Assoc Disord; 2008; 22(1):47-53. PubMed ID: 18317246
[TBL] [Abstract][Full Text] [Related]
12. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
Lewczuk P; Kornhuber J; Vanderstichele H; Vanmechelen E; Esselmann H; Bibl M; Wolf S; Otto M; Reulbach U; Kölsch H; Jessen F; Schröder J; Schönknecht P; Hampel H; Peters O; Weimer E; Perneczky R; Jahn H; Luckhaus C; Lamla U; Supprian T; Maler JM; Wiltfang J
Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
[TBL] [Abstract][Full Text] [Related]
13. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
14. Clinical Experience with Cerebrospinal Fluid Aβ42, Total and Phosphorylated Tau in the Evaluation of 1,016 Individuals for Suspected Dementia.
Tariciotti L; Casadei M; Honig LS; Teich AF; McKhann Ii GM; Tosto G; Mayeux R
J Alzheimers Dis; 2018; 65(4):1417-1425. PubMed ID: 30149454
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal changes of CSF biomarkers in memory clinic patients.
Bouwman FH; van der Flier WM; Schoonenboom NS; van Elk EJ; Kok A; Rijmen F; Blankenstein MA; Scheltens P
Neurology; 2007 Sep; 69(10):1006-11. PubMed ID: 17785669
[TBL] [Abstract][Full Text] [Related]
16. Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations.
Rosso SM; van Herpen E; Pijnenburg YA; Schoonenboom NS; Scheltens P; Heutink P; van Swieten JC
Arch Neurol; 2003 Sep; 60(9):1209-13. PubMed ID: 12975285
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
[TBL] [Abstract][Full Text] [Related]
18. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.
Stomrud E; Hansson O; Zetterberg H; Blennow K; Minthon L; Londos E
Arch Neurol; 2010 Feb; 67(2):217-23. PubMed ID: 20142530
[TBL] [Abstract][Full Text] [Related]
19. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
[TBL] [Abstract][Full Text] [Related]
20. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
